RP-3 is under clinical development by Replimune and currently in Phase I for Gastrointestinal Tract Cancer.
Labcorp inks $237.5M buyout of Opko’s reproductive, women’s health testing assets
Dive Brief: Labcorp struck a deal Thursday to acquire clinical diagnostics, reproductive and women’s health testing assets from Bioreference Health, a subsidiary of Opko Health,